Navigation Links
Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
Date:12/4/2013

BUFFALO, N.Y., Dec. 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced today that they have received Orphan Drug designation for KX02 for the treatment of gliomas, which are the most common and aggressive form of brain cancer.  Orphan drug status qualifies Kinex for seven years of exclusivity after formal marketing approval, as well as further development incentives. KX02, a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including those that are resistant to Temozolomide (T98G), the most widely used chemotherapy for the treatment of malignant glioma.  In a well-established brain tumor animal model, KX02 consistently clears brain tumors after 4 weeks of therapy, in 30-60% of treated animals. These studies showed that KX02 induced more necrosis compared to Temodar, and also generated an immune response to the glioblastoma tumor cells. Pharmacokinetic studies showed that KX02 is absorbed orally and has 76% penetration into brain tissue from plasma. 

Dr. David Hangauer, Chief Scientific Officer of Kinex stated, "Receiving Orphan Drug Status for KX02 speaks to the need for new treatment options for patients with gliomas. KX02 is a novel compound with good potential for these patients in terms of generating a durable immune response to tumor cells in mice that allow the animals to live to their full life expectancy without tumor recurrence or further drug treatment.  We are looking forward to moving this novel compound into the clinic."

"This is an important regulatory milestone for Kinex," stated Dr. Lyn Dyster, Senior VP of Operations at Kinex.  "The orphan drug designation will facilitate our goal of developing KX02 as a potentially new and effective treatment for patients with gliomas. The standard treatment for glioblastoma consists of surgical removal of the tumor bulk, followed by radiation and chemotherapy with temozolomide.  KX02 has demonstrated the ability to clear gliomas in a well-established animal model and also prevent tumor recurrence in these animals and we are excited to move this novel compound into the clinical setting.   We have worked diligently with clinical sites to establish the trial protocols and expect to initiate a Phase 1 trial imminently."

XiangXue Pharmaceuticals is Kinex's collaborative development partner for KX02 in China and has an exclusive license from Kinex for this territory. Mr. YongHui Wang, Chairman and CEO of XiangXue Pharmaceuticals added, "Kinex has been an excellent collaborative partner.  Their ability to develop novel drugs and work closely with regulatory agencies continues to impress us and we are very pleased that the FDA has granted Orphan Drug Status for KX02. Glioblastoma is an aggressive cancer with few treatment alternatives.  In fact, the average patient with malignant glioblastoma has a life expectancy of less than 12 months once they are diagnosed with the disease.  I am hopeful, based on promising animal studies, that KX02 can provide a new treatment option for this devastating disease. XiangXue is developing our IND application for the Chinese State FDA and we are planning to initiate KX02 trials for Chinese patients with brain tumor patients in 2014."

About orphan drug status:
FDA Orphan Drug Designation is designed to encourage the development of drugs involved in the diagnosis, prevention or treatment of a medical condition affecting fewer than 200,000 people in the United States. This designation will provide Kinex with seven years of marketing exclusivity for KX02 in the treatment of glioblastoma patients if KX02 is approved for this indication. Orphan drug designation also affords the potential to obtain tax credits related to development expenses, the potential reduction in FDA user fees and the opportunity to obtain grant funding to defray clinical expenses.

About Kinex:
Founded in 2002, Kinex is a global biotechnology company focused on the development and commercialization of next generation oral therapies for cancer and immunomodulatory diseases. The company is dedicated to delivering innovative drugs that can have a life-changing impact on patients.  Through consistent investment in R&D and scientific excellence the company is developing important drug programs that address unmet medical needs and focus on critical factors that can improve outcomes.   It is Kinex's goal to have oral oncology treatment and maintenance platforms as well as  breakthrough drugs involving the immune system to help patients prevail over their disease. Kinex and its partners currently have four global clinical trials ongoing at highly regarded medical institutions.    Investigational compounds are being studied in a variety of solid tumors, including breast cancer, ovarian cancer, colon cancer, glioblastoma multiforme and gastric cancer.  More information of Kinex can be found at www.kinexpharma.com

About XiangXue:
Guangzhou XiangXue Pharmaceutical Co., Ltd (XPH) is a publicly traded pharmaceutical company headquartered in Guangzhou, China. The primary business of the Company is the manufacturing and marketing of pharmaceutical products, including herbal medicines, western medicines and biomedical engineering products. The company is actively expanding its product pipeline through research and development efforts and through in-licensing in areas of unmet medical needs. More information on XPH can be found at www.xphcn.com


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
2. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
3. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
4. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
5. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
6. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
7. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
8. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
9. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
10. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
11. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Open Access Journal ... Neurophysiology  Elsevier , a world-leading provider ... today announced the launch of Clinical Neurophysiology ... that focuses on clinical practice issues in clinical neurophysiology. ... series, normal values and didactic reviews. It is an ...
(Date:5/23/2016)... 23, 2016 According to ... Market by Product (Wheelchair, Scooters, Medical Beds, Bathroom ... Critical Care, Wound), Accessories (Lifting, Transfer) & by ... published by MarketsandMarkets, the patient handling equipment market ... 2021 at a CAGR of 10.5% during the ...
(Date:5/23/2016)... Transparency Market Research has published ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... report, the exocrine pancreatic insufficiency market is anticipated to ... 2023 to reach US$2.85 Bn by 2023. ... the deficiency of the exocrine pancreatic enzymes, causing failure ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... has seen a significant spike in their clients' employee participation for their wellness ... health screening by implementing a high-deductible health plan with outcome-based deductible incentives. As ...
(Date:5/25/2016)... ... ... Stern Environmental Group , of Secaucus, New Jersey, working in conjunction ... Real Time Monitoring (RTM) Device. Stern Environmental Group will sell the first monitoring ... use in dormitories, shelters, and nursing homes for real time bedbug monitoring in May ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... (Rudy) Cifolelli has joined the company as Vice President of Sales. Cifolelli’s ... U.S. and international sales in the rapidly expanding field of organizational social engineering. ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and ... for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of ... roots. , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth ...
(Date:5/24/2016)... ... , ... How to Write Error Free Procedures, **Presented by Ginette M. Collazo ... is known to be the major cause of quality and production losses in many ... human performance problems can be prevented. , How to Write Error Free Procedures, part ...
Breaking Medicine News(10 mins):